1 In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs 2 In Phase 1 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point 3 Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels 4 In Phase 1 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMCs 5 Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels 6 In Phase 1 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point 7 In Phase 1 participants, GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 (anti-S1 and anti-RBD) binding antibody levels 8 Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination 9 Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination 10 Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination 11 Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination 12 Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination 13 Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination 14 Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination 15 Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination 16 Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination 17 Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination 18 GMR of SARS CoV 2 neutralizing titers in the 2 age groups (12-15 years of age to 16-25 years of age) 19 Incidence of asymptomatic SARS CoV-2 infection based on N binding antibody seroconversion in participants with no serological or virological evidence of past SARS CoV-2 infection or confirmed COVID-19 prior to 1 month after receipt of the second dose 20 Incidence of asymptomatic SARS CoV-2 infection based on central laboratory-confirmed NAAT in participants with no serological or virological evidence (up to the start of the asymptomatic surveillance period) of past SARS-CoV-2 infection 21 Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after a third dose of BNT162b2 at 30 µg compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals 22 Noninferiority of the SARS-CoV-2 reference strain neutralizing titers after one dose of BNT162b2SA compared to after 2 doses of BNT162b2, in the same individuals 23 Comparison of the SARS-CoV-2 SA strain neutralizing titers after 1 dose of BNT162b2SA to after a third dose of BNT162b2 at 30 µg 24 Comparison of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals 25 Comparison of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA to after 2 doses of BNT162b2 26 Comparison of the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2SA to after 2 doses of BNT162b2
1 In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs 2 In Phase 1 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point 3 Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels 4 In Phase 1 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMCs 5 Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels 6 In Phase 1 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point 7 In Phase 1 participants, GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 (anti-S1 and anti-RBD) binding antibody levels 8 Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination 9 Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination 10 Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination 11 Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination 12 Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination 13 Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination 14 Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination 15 Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination 16 Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination 17 Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination 18 GMR of SARS CoV 2 neutralizing titers in the 2 age groups (12-15 years of age to 16-25 years of age) 19 Incidence of asymptomatic SARS CoV-2 infection based on N binding antibody seroconversion in participants with no serological or virological evidence of past SARS CoV-2 infection or confirmed COVID-19 prior to 1 month after receipt of the second dose 20 Incidence of asymptomatic SARS CoV-2 infection based on central laboratory-confirmed NAAT in participants with no serological or virological evidence (up to the start of the asymptomatic surveillance period) of past SARS-CoV-2 infection 21 Noninferiority of the SARS-CoV-2 SA strain neutralizing titers after a third dose of BNT162b2 at 30 µg compared to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals 22 Noninferiority of the SARS-CoV-2 reference strain neutralizing titers after one dose of BNT162b2SA compared to after 2 doses of BNT162b2, in the same individuals 23 Comparison of the SARS-CoV-2 SA strain neutralizing titers after 1 dose of BNT162b2SA to after a third dose of BNT162b2 at 30 µg 24 Comparison of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA to the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2, in the same individuals 25 Comparison of the SARS-CoV-2 SA strain neutralizing titers after 2 doses of BNT162b2SA to after 2 doses of BNT162b2 26 Comparison of the SARS-CoV-2 reference strain neutralizing titers after 2 doses of BNT162b2SA to after 2 doses of BNT162b2
In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs Through 2 years after the final dose In Phase 1 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point Through 2 years after the final dose Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels Through 2 years after the final dose In Phase 1 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMCs Through 2 years after the final dose Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels Through 2 years after the final dose In Phase 1 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point Through 2 years after the final dose In Phase 1 participants, GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 (anti-S1 and anti-RBD) binding antibody levels Through 2 years after the final dose Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination From 14 days after the second dose of study intervention to the end of the study, up to 2 years Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination From 14 days after the second dose of study intervention to the end of the study, up to 2 years Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination From 7 days after the second dose of study intervention to the end of the study, up to 2 years Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination From 14 days after the second dose of study intervention to the end of the study, up to 2 years Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination From 7 days after the second dose of study intervention to the end of the study, up to 2 years Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination From 14 days after the second dose of study intervention to the end of the study, up to 2 years Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination From 7 days after the second dose of study intervention to the end of the study, up to 2 years Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination From 14 days after the second dose of study intervention to the end of the study, up to 2 years Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination From 7 days after the second dose of study intervention to the end of the study, up to 2 years Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination From 14 days after the second dose of study intervention to the end of the study, up to 2 years
Du måste vara medlem för att kunna kommentera